Literature DB >> 11276839

Surgical treatment of giant cell tumours of the thoracic and lumbar spine: report of nine patients.

M W Fidler1.   

Abstract

Giant cell tumours involving vertebral bodies are still difficult to treat, though results are gradually improving. The object of this study was to assess the results of "complete excision", both of previously untreated giant cell tumours and of recurrences, and to consider the possible effects of any tumour contamination during operation. Nine consecutive patients with giant cell tumours of the thoracic and lumbar spine were treated surgically between 1986 and 1995. Four of these patients were referred with recurrent tumours. All operations aimed at complete resection of the tumour, where possible an en-bloc approach was used. The spines were reconstructed with autografts and instrumentation. All patients were regularly reviewed as part of an on-going study. Following the five operations for previously untreated tumours ("primary" operations), there were no local recurrences, but one patient died of pulmonary metastases. One of the four patients operated upon for a recurrence developed a further recurrence, which was excised 2 1/2 years ago. It would seem that giant cell tumours of the thoracic and lumbar spine, including recurrences, should be treated by complete excision. The en-bloc approach is the safest technique. Where an intralesional component is unavoidable, total removal of the (pseudo)capsule should be ensured by preliminary extralesional dissection. Any tumour spill should be meticulously removed. The use of frozen sections to check resection margins is advisable.

Entities:  

Mesh:

Year:  2001        PMID: 11276839      PMCID: PMC3611477          DOI: 10.1007/s005860000206

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  25 in total

Review 1.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

2.  Giant cell tumor of the fifth lumbar vertebra with a three-year follow-up: case report and review of the literature.

Authors:  Michael Athanassacopoulos; Georgios K Triantafyllopoulos; Spyridon G Pneumaticos
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-03-25

Review 3.  Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.

Authors:  Christopher Martin; Edward F McCarthy
Journal:  Iowa Orthop J       Date:  2010

Review 4.  Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal.

Authors:  Stefano Boriani; Riccardo Cecchinato; Fabrizio Cuzzocrea; Stefano Bandiera; Marco Gambarotti; Alessandro Gasbarrini
Journal:  Eur Spine J       Date:  2019-05-16       Impact factor: 3.134

5.  Total en bloc spondylectomy.

Authors:  Morgan Jones; James Holton; Simon Hughes; Marcin Czyz
Journal:  J Spine Surg       Date:  2018-09

6.  Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis.

Authors:  K Zhang; M Zhou; H Chen; G Wu; K Chen; H Yang
Journal:  Clin Transl Oncol       Date:  2015-03-05       Impact factor: 3.405

Review 7.  Tumors of the osseous spine.

Authors:  Narayan Sundaresan; Stephano Boriani; Allen Rothman; Robert Holtzman
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

8.  Treatment of giant cell tumor of bone: Current concepts.

Authors:  Ajay Puri; Manish Agarwal
Journal:  Indian J Orthop       Date:  2007-04       Impact factor: 1.251

9.  Giant cell tumor of the spine: A review of 9 surgical interventions in 6 cases.

Authors:  Shekhar Y Bhojraj; Abhay Nene; Sheetal Mohite; Raghuprasad Varma
Journal:  Indian J Orthop       Date:  2007-04       Impact factor: 1.251

10.  Treatment options for recurrent giant cell tumors of bone.

Authors:  Maurice Balke; Helmut Ahrens; Arne Streitbuerger; Gabriele Koehler; Winfried Winkelmann; Georg Gosheger; Jendrik Hardes
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.